Previous product
Back to products
Opdivo (Nivolumab)
CHF624.00
Next product
Rubraca (rucaparib)
CHF1,908.74
Perjeta (Pertuzumab)
CHF3,036.09
Perjeta (pertuzumab) is a medication used for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer.
Category: Oncology
Reviews
There are no reviews yet.